REG - Medpal AI PLC - Trading Update and At The Market Facility

Medpal AIAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251204:nRSD1405Ka&default-theme=true

RNS Number : 1405K  Medpal AI PLC  04 December 2025

4 December 2025

MedPal AI plc

("MedPal AI" or the "Company")

Trading Update - Pharmacy Operations

MedPal AI Deploys Google's Vertex AI

ATM Facility

 

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence
("AI") company focused on health and wellness management, is pleased to
provide a trading update on its pharmacy operations for November 2025 and also
announce that its wholly owned subsidiary, MedPal Limited has deployed Google
Cloud's Vertex AI platform on WhatsApp Business. The Directors believe that
this makes the MedPal.clinic service, which will be available free to patients
24/7, the first UK registered online pharmacy to integrate advanced AI triage
via WhatsApp.  The Company also announces that it has established an
At-The-Market (ATM) equity issuance facility through its broker, Clear Capital
Markets Limited ("Clear Capital").

Trading Update - Pharmacy Operations

MedPal Limited's pharmacy, MedPal Pharmacy, is now registered with GPhC, with
the necessary registration and intellectual property prescription services for
certain medications under electronic record systems Patient Group Directions.
It also has a Clinical Services team with qualified Independent Prescribers to
issue prescriptions and fulfil them.

During November 2025, MedPal Limited processed 28,789 prescription orders
through its automated pharmacy operations, with an average item value of
£9.72, representing approximately £280,000 of revenue. This represents
strong month-on-month growth of more than 90% and demonstrates the increasing
demand for the Company's AI-enhanced pharmacy services.

The continued scaling of prescription volumes reflects both the successful
integration of the NHS Distance Selling Pharmacy ("DSP") contract and growing
uptake of the Company's private weight loss service launched via
MedPal.clinic.

Adoption of Vertex AI

MedPal AI has deployed Google's Vertex AI to power intelligent clinical triage
through a dedicated WhatsApp Business number (07300 100 600). The Company has
built and trained proprietary machine learning models on its clinical data
using Google's enterprise AI platform.

The technology delivers sophisticated patient assessment that seamlessly hands
over to qualified clinicians for prescribing decisions, combining AI
efficiency with clinical safety.

MedPal.clinic now offers patients free 24/7 WhatsApp access to:

·      AI-powered health assessment using Google's Vertex AI;

·      intelligent triage across multiple medical conditions;

·      direct connection to prescribing clinicians when needed; and

·      full medication fulfilment through MedPal's pharmacy operations.

MedPal.clinic's initial focus will be weight-loss treatments including GLP-1
therapies, with the platform designed to expand across additional therapeutic
areas such as men's health (including erectile dysfunction and hair loss
treatments), women's health (such as hormone replacement therapy and
contraception), dermatology (for conditions like acne, psoriasis, and eczema),
and respiratory issues (including asthma inhalers and allergy medications).
The UK weight-loss treatment market has grown significantly recently with the
offer of GLP-1 therapies.

Technology Infrastructure

The service combines two leading technology platforms:

·      Google Cloud Vertex AI: Enables MedPal.clinic to build, train and
scale proprietary machine learning models on clinical data; and

·      WhatsApp Business: Provides 24/7 patient access through the UK's
most widely used messaging platform.

This integration positions MedPal.clinic as the one of the UK's most
technologically advanced online pharmacy operation.

ATM Facility

ATM facilities are common in certain jurisdictions such as the US and Canada,
enabling companies to incrementally sell newly issued shares on a stock
exchange through a designated broker-dealer at prevailing market prices and on
an as-and-when-needed basis.

The Company's recently established online pharmaceutical subsidiary, MedPal
Limited, operating MedPal Pharmacy and Medpal.clinic, is experiencing high
demand. Additional working capital provided by an ATM would provide
flexibility for MedPal Pharmacy to hold greater levels of stock and expand its
product line and to undertake marketing campaigns to grow the pharmacy and
clinic part of the business more quickly.

On 3 December 2025, the Company entered into an ATM-like facility agreement
with Clear Capital (the "Agreement") pursuant to which, Clear Capital will
execute sales following receipt of instruction from the Company, via the
London Stock Exchange. The aggregate gross proceeds of the facility shall not
exceed £2,000,000 and the floor price per ATM Share has been set at 5p. The
facility is effective for a period of 24 months, unless terminated earlier
pursuant to the Agreement.

Pursuant to the ATM facility, new ordinary shares in the Company ("ATM
Shares") will be made available for sale via the Company's broker on a tranche
by tranche basis. Any share sales to be made to the market will be close to
the mid-market price at the time and not below a minimum price to be set by
the Company for each tranche. Any issuance under the facility will be carried
out in a controlled manner and within prudent internal volume parameters,
ensuring that sales occur only when market conditions are considered by Clear
Capital to be favourable and in a way that supports an orderly market. The
Company does not intend to sell ATM Shares in a manner that would place
unnecessary pressure on the share price.

Periodically, once an order has been placed under the ATM facility, the
Company will issue an RNS to confirm the number of ATM Shares issued, with
details of their average sale price and the net proceeds raised by the
Company.  Once issued, application for admission to trading on AIM will be
sought for each order of ATM Shares. Commission in line with market rates will
be retained from the gross proceeds of sales by Clear Capital with the net
proceeds being transferred to the Company.

Upon successful completion of the ATM facility, the Company will grant up to
10m warrants to Clear Capital. The precise number of warrants to be issued
will depend on the total gross proceeds raised under the facility, calculated
in accordance with the terms of the Agreement. No warrants will be issued
until completion of the facility.

The ATM facility may be withdrawn by the Company without notice at any time.

Jason Drummond, CEO of MedPal AI, said:

"We are pleased with MedPal Limited's performance to date, which shows
continued strong growth in prescription volumes. Processing nearly 29,000
prescription orders in November 2025 demonstrates the scalability of our
automated dispensing infrastructure and validates our integrated healthcare
model. The combination of our NHS contract, our state-of-the-art robotic
dispensing technology, and AI-powered telehealth services continues to gain
traction in the market. In addition, the deployment of Google's Vertex AI
platform on WhatsApp Business positions MedPal.clinic as a highly
technologically advanced online pharmacy.

"We have built proprietary models with the potential to deliver sophisticated
triage at scale whilst maintaining full clinical oversight and we remain
focused on sustainable growth. The ATM facility will provide us with flexible
funding to accelerate this, to expand our innovative offerings, and meet
rising demand, whilst maintaining the highest standards of patient safety and
service quality."

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer     Via Square1 Consulting

 Cairn Financial Advisers LLP                +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited               +44 (0) 20 3869 6080

 Bob Roberts/ Nick Josh

 Square1 Consulting                          +44 (0) 20 7929 5599

 David Bick                                  +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

 

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

 

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTQXLFBELLEFBB



            Copyright 2019 Regulatory News Service, all rights reserved